Immunochemotherapy-associated protein patterns in tumour tissue and serum of patients with metastatic renal cell carcinoma

Archives of Physiology and Biochemistry

Volumn 116, Issue 4-5, 2010, Pages 197-207

  Walter, Martina ^a   Heinze, Christian ^a   Steiner, Thomas ^a   Pilchowski, Rico ^a   Von Eggeling, Ferdinand ^a   Wunderlich, Heiko ^a   Junker, Kerstin ^a  

^a University Hospitals Jena   (Germany)

Author keywords

Biomarker; Proteomic pattern; SELDI TOF MS

Indexed keywords

ANTINEOPLASTIC AGENT; CAVEOLIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREALBUMIN; SERUM AMYLOID A; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BLOOD; FEMALE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MASS SPECTROMETRY; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROTEIN MICROARRAY; REMISSION; SECRETION; TREATMENT OUTCOME; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CAVEOLIN 1; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREALBUMIN; PROGNOSIS; PROTEIN ARRAY ANALYSIS; REMISSION INDUCTION; SERUM AMYLOID A PROTEIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TREATMENT OUTCOME;

EID: 78649250228     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.3109/13813455.2010.513392     Document Type: Article

References (34)

1. Andreasen PA, Egelund R, Petersen HH. (2000). The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57:25-40.
2. Atzpodien J, Kirchner H, Jonas U, Bergman L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Muller S. C. et al. (2004). Interleukin-2-and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: A prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22:1188-94.
3. Bergstrom A, Hsieh CC, Lindblad P, Lu CM, Cook NR, Wolk A. (2001). Obesity and renal cell cancer - a quantitative review. Br J Cancer 85:984-90.
4. Bourry J, Milano G, Caldani C, Schneider M. (1982). Assessment of nutritional proteins during the parenteral nutrition of cancer patients. Ann Clin Lab Sci 12:158-62.
5. Campbell L, Gumbleton M, Grifths DF. (2003). Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confned renal cell carcinoma. Br J Cancer 89:1909-13.
6. Cohen AW, Razani B, Schubert W, Williams TM, Wang XB, Iyengar P, Brasaemle DL, Scherer PE, Lisanti MP. (2004). Role of caveolin-1 in the modulation of lipolysis and lipid droplet formation. Diabetes 53:1261-70.
7. Escudier B. (2008). Signaling inhibitors in metastatic renal cell carcinoma. Cancer J 14:325-9.
8. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA et al. (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-34.
9. Fellah H, Omar S, Feki M, Abderrahim E, Ben Abdallah T, Massy ZA, Lacour B, Ben Maiz H, Kaabachi N, Mebazaa A. (2008). Is serum transthyretin a reliable marker of nutritional status in patients with end-stage renal disease? Clin Biochem 41:493-7.
10. Gericke B, Raila J, Sehouli J, Haebel S, Konsgen D, Mustea A, Schweigert FJ. (2005). Microheterogeneity of transthyretin in serum and ascitic fuid of ovarian cancer patients. BMC Cancer 5:133.
11. Grignon DJ, Eble JN, Bonsib SM, Moch H. (2004). Clear cell renal cell carcinoma. In: Eble Jr, SG, Epstein JI, Sesterhenn IA, editors. World Health Organization Classifcation of Tumours. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon, France: IARC Press.
12. Gu JR, Jiang HQ, He LP, Li DZ, Zhou XM, Dai WL, Qian LF, Chen YQ, Schweinfest C, Papas T. (1991). Transthyretin (prealbumin) gene in human primary hepatic cancer. Sci China B 34:1312-8.
13. Heng DY, Rini BI, Garcia J, Wood L, Bukowski RM. (2007). Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma. Clin Genitourin Cancer 5:446-51.
14. Hofmockel G, Langer W, Teiss M, Gruss A, Frohmuller HG. (1996). Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fuorouracil. J Urol 156:18-21.
15. Ingenbleek Y, Young V. (1994). Transthyretin (prealbumin) in health and disease: Nutritional implications. Annu Rev Nutr 14:495-533.
16. Johannsen M, Florcken A, Bex A, Roigas J, Cosentino M, Ficarra V, Kloeters C, Rief M, Rogalla P, Miller K, Grunwald V. (2009). Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol 55:1430-38.
17. Junker K, Gneist J, Melle C, Driesch D, Schubert J, Claussen U, von Eggeling F. (2005). Identifcation of protein pattern in kidney cancer using Protein Chip arrays and bioinformatics. Int J Mol Med 15:285-90.
18. Kiernan UA, Tubbs KA, Nedelkov D, Niederkofer EE, Nelson RW. (2003). Detection of novel truncated forms of human serum amyloid A protein in human plasma. FEBS Lett 537:166-70.
19. Los M, Zeamari S, Foekens JA, Gebbink MF, Voest EE. (1999). Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene. Cancer Res 59:4440-45.
20. Mikisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. (2001). Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358:966-70.
21. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukovski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST et al. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-24.
22. Oberneder R, Siebels M, Hofstetter A. (1998). Adjuvante Terapie des Nierenzellkarzinoms. Urologe B 38:342-46.
23. Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H. (2005). Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. J Urol 174:461-5.
24. Patard JJ, Rioux-Leclercq N, Fergelot P. (2006). Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 49:633-43.
25. Rasmuson T, Grankvist K, Jacobsen J, Olsson T, Ljungberg B. (2004). Serum insulin-like growth factor-1 is an independent predictor of prognosis in patients with renal cell carcinoma. Acta Oncol 43:744-8.
26. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ et al. (2006). Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-12.
27. Rossi L, Martin BM, Hortin GL, White RL, Foster M, Moharram R, Stroncek D, Wang E, Marincola FM, Panelli MC. (2006). Infammatory protein profle during systemic high dose interleukin-2 administration. Proteomics 6:709-20.
28. Suresh UR, Wilkes S, Hasleton PS. (1991). Prealbumin in the diagnosis of bronchopulmonary carcinoid tumours. J Clin Pathol 44:573-5.
29. Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A, Kratzin H, Deeg M, Kuczyk M, Mueller GA et al. (2004). Serum protein profling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 84:845-56.
30. Tourani JM, Pfster C, Berdah JF, Benhammouda A, Salze P, Monnier A, Paule B, Guillet P, Chretien Y, Brewer Y et al. (1998). Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fuorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group. J Clin Oncol 16:2505-13.
31. Vermaat JS, van der Tweel I, Mehra N, Sleijfer S, Haanen JB, Roodhart JM, Engwegen JY, Korse CM, Langenberg MH, Kruit W et al. (2010). Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. Ann Oncol 21:1472-81.
32. Wagner SN, Atkinson MJ, Tanner S, Schmitt M, Wilhelm O, Rotter M, Hofer H. (1996). Type-1 plasminogen activator inhibitor in human renal cell carcinoma. J Pathol 179:95-9.
33. Weikert S, Boeing H, Pischon T, Weikert C, Olsen A, Tjonneland A, Overvad K, Becker N, Linseisen J, Trichopoulou A et al. (2008). Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol 167:438-46.
34. Zhang Z, Bast Jr RC, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY et al. (2004). Tree biomarkers identifed from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64:5882-90.